Peginterferon Alfa 2B
Mechanism :
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two JAK (Janus kinase) tyrosine kinases (JAK1 and TYK2). These transphosphorylase themselves and phosphorylates the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Indication :
- Chronic Hepatitis B infection.
- Hepatitis C infection
Contraindications :
Peginterferon alfa-2b is contraindicated in conditions like Autoimmune hepatitis, Hypersensitivity to the drug.
Dosing :
Hepatitis C infection:
>3 years: 60 mcg/m² SC once weekly plus
ribavirin.
Adverse Effect :
Infection, headache, fatigue, nausea, vomiting, fever, myalgia, anxiety, asthenia, neutropenia, rigors, injection site reactions.
Interaction :
Aminophylline: Interferon increases the effect and toxicity of theophylline.
Dyphylline: Interferon increases the effect and toxicity of theophylline.
Oxtriphylline: Interferon increases the effect and toxicity of theophylline.
Theophylline: Interferon increases the effect and toxicity of theophylline.
Hepatic Dose :
Decompensated liver disease or autoimmune hepatitis: Use is contraindicated.
Hepatic decompensation or severe hepatic injury during treatment (Child-Pugh class B or C): Discontinue immediately